Neuraxis, INC Form 4 insider transactions

Director Gilad Aharon acquired 234,221 shares of Neuraxis common stock through Series B Preferred Stock dividend distributions.

Neuraxis, Inc. Chief Financial Officer, Timothy Henrichs, reported the acquisition of 7,593 shares of common stock on April 1, 2026.

Neuraxis CRO, CCO, CPO Thomas Carrico acquired 667 shares of common stock at $1.96 per share.

Neuraxis, Inc. CEO Brian Carrico acquired 8,060 shares of common stock on April 1, 2026, for $1.96 per share.

Neuraxis, Inc. Chief Medical Officer and SVP of Science & Technology, Adrian Miranda, was granted 47,569 restricted stock units as compensation.

Neuraxis Director Bradley Mitchell Watkins acquired 21,598 shares of common stock as compensation for his services.

Neuraxis Director Jane Elizabeth Keyser acquired 21,598 shares of common stock as compensation for her services.

Neuraxis, Inc. Chief Financial Officer Timothy Henrichs was granted 75,231 restricted stock units, vesting over three years.

Neuraxis, Inc. officer Thomas Carrico received a grant of 47,569 restricted stock units vesting over three years.

Neuraxis, Inc. CEO Brian Allen Carrico received a grant of 94,173 restricted stock units as part of his compensation package.

A Neuraxis director and 10% owner acquired 80,000 shares of common stock over two days in February 2026, totaling approximately $382,800.

Neuraxis, INC Director Gil Aharon acquired 21,598 common shares as compensation for services, increasing his beneficial ownership to 307,736 shares.

Neuraxis Director Kristin A. Ferge acquired 21,598 shares of common stock as compensation, increasing her beneficial ownership.

A fund advised by Neuraxis Director Gil Aharon purchased 286,138 common shares at $3.52 each.

Neuraxis, Inc. CEO Brian Allen Carrico received grants of 170,659 Restricted Stock Units under incentive plans, vesting over 36 months.

Neuraxis, INC Director Kristin Ferge acquired 13,157 shares of common stock at $2.85 per share as compensation for her services.

Neuraxis's Chief Financial Officer, Timothy Henrichs, was granted 242,017 restricted stock units as part of compensation, hiring, bonus, and long-term incentive plans.

Neuraxis Director Jane Keyser acquired 13,157 shares of common stock as compensation, increasing her direct beneficial ownership to 24,737 shares, though the transaction was reported with a significant delay.

Neuraxis's CMO and SVP of Science & Technology, Adrian Miranda, was granted a total of 75,000 Restricted Stock Units under various incentive plans.

Neuraxis Director Bradley Mitchell Watkins has filed a Form 4 indicating a planned acquisition of 13,157 shares of common stock at $2.85 per share on January 17, 2025, as compensation for his services.

Neuraxis, Inc. disclosed the grant of 72,435 restricted stock units to CRO, CCO, and CPO Thomas Carrico under incentive plans.

Masimo Corp., a 10% owner and director of Neuraxis, Inc., reported the complete divestment of its holdings in Neuraxis through the sale of over 821,000 common shares and the exercise and subsequent sale of pre-funded warrants.

Brian Hannasch, a Director and 10% Owner of Neuraxis, INC, has purchased 355,556 shares of common stock, increasing his total beneficial ownership to 1,131,522 shares.

Brian Hannasch, a director and 10% owner of Neuraxis INC, acquired 18,065 shares of common stock at an average price of $1.7299 on April 21, 2025, increasing his total holdings to 775,966 shares.

Director Kristin A. Ferge receives 1,183 shares of Neuraxis, Inc. common stock as compensation for services through March 31, 2024.

Director Jane Elizabeth Keyser received 11,580 shares of Neuraxis, Inc. common stock as compensation for services provided through March 31, 2024.

Director Bradley Mitchell Watkins acquired 11,580 shares of Neuraxis, Inc. common stock on June 28, 2024, as compensation for services.

Brian Hannasch, a director of Neuraxis, INC, reports acquiring 75,000 shares of common stock on February 20, 2024, increasing his total holdings to 757,901 shares.